The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.

Provided herein is a method for stabilising a single stranded RNA (ssRNA) by encapsidation of the ssRNA with a tobamovirus coat protein to obtain a pseudovirion (PsV), the method comprising expressing a tobamovirus coat protein and the ssRNA comprising a tobamovirus encapsidation origin (OriA), wherein the expressed tobamovirus coat protein interacts with the OriA sequence on the ssRNA to initiate encapsidation of the ssRNA by the tobamovirus coat protein, thereby forming a pseudovirion. The PsVs produced according to the method can be used as a diagnostic control composition, where the ssRNA is a sequence detected by a molecular diagnostic assay. The pseudovirions may also be used as a vaccine to elicit an immune response in a subject, and in pharmaceutical compositions to be administered to a subject.